Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.

Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.

Novavax (NVAX) stock in focus as the company boosts 2025 revenue outlook after better than expected Q3 revenue driven by ...

CEO John C. Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may translate into big problems for Johnson & Johnson, Merck, and other ...

IAVI reports its single-dose Lassa fever vaccine is safe and effective, paving way for advanced trials across West Africa.

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd ...

Seasoned leader, philanthropist, and mother to drive the nation's leading tutoring and test prep provider into its next era of growth and innovation ORADELL, NJ / ACCESS Newswire / October 30, 2025 / ...

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...